1	Proteome-wide and mendelian randomisation analyses of chronic widespread pain:		
2	diagnosis, prognosis, and drug target discovery		
3			
4	Li Chen <sup>1,2</sup> , Eoin Kelleher <sup>3</sup> , Ruogu Meng <sup>4</sup> , Duanke Liu <sup>5</sup> , Yuchen Guo <sup>1</sup> , Yunhe Wang <sup>6</sup> ,		
5	Yaoqing Gao <sup>6</sup> , Zhe Huang <sup>6</sup> , Zhu Liang <sup>7</sup> , Shuai Yuan <sup>8,9</sup> , Chao Zeng <sup>10</sup> , Guanghua Lei <sup>10</sup> ,		
6	Jun Ma <sup>2</sup> , Yanhui Dong <sup>2</sup> , Anushka Irani <sup>1,11</sup> , Junqing Xie <sup>1,12*</sup> , Daniel Prieto-Alhambra		
7	1,13&		
8	1. Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford,		
9	NDORMS, University of Oxford, Oxford, UK		
10	2. Institute of Child and Adolescent Health, School of Public Health, Peking University		
11	3. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK		
12	4. National Institute of Health Data Science, Peking University, Beijing, China		
13	5. Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren		
14	Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and		
15	Visual Sciences, Beijing, China		
16	6. Nuffield Department of Population Health, University of Oxford, Oxford, UK		
17	7. Nuffield Department of Medicine, University of Oxford, Target Discovery Institute,		
18	Center for Medicines Discovery, Oxford, United Kingdom		
19	8. Department of Surgery, Perelman School of Medicine at the University of Pennsylvania,		
20	PA, USA		
21	9. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden		
22 23	10. Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China		
24	11. Division of Rheumatology, Mayo Clinic Florida, Florida, USA		
25	12. The Queen's College, University of Oxford, Oxford, UK		
26	13. Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the		
27	Netherlands		
28			
29			
30	& Joint senior authorship		
31	*Correspondence to:		
32	DPhil. Junqing Xie		
33	Email: Junqing.xie@ndorms.ox.ac.uk		

- 34 Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS,
- 35 University of Oxford, Oxford, UK;

### 36 Abstract

37 Chronic widespread pain (CWP) remains challenging due to its heterogenous causes and 38 complex mechanisms. We analysed 2,923 plasma proteins from 29,254 UK Biobank 39 participants. We first identified 811 proteins correlated with the presence of CWP cross-40 sectionally. We then created a sparse (top 10 proteins) and intricate (all significant proteins) 41 proteomic-based score (ProtS) for CWP, both outperforming and improving the traditional 42 clinical score (AUC: 0.82 and 0.88 vs 0.81 individually, and 0.87 and 0.92 in combination). 43 Prospectively, the ProtS was associated with increased risks of a spectrum of pain traits, 44 including dimensions from pain onset, progression and intensity, up to 13-years of follow-up; 45 More importantly, we identified distinct proteomic signatures for nociplastic pain compared 46 to nociceptive and neuropathic pain. For the individual proteins, carbonic anhydrase 14 47 (CA14) and leptin appeared as promising casual CWP biomarkers as triangulated by 48 Mendelian randomisation and colocalization analyses. Lastly, our drug-repurposing analysis 49 identified ten potential candidates for CWP therapies, calling for further research including 50 randomised controlled trials. Although no CA14 agonists are currently available, CA14 51 remains a promising target, warranting further efforts to explore its role in pain modulation.

## 52 Introduction

53 Chronic pain affects 27.5% of the global population and is one of the leading causes of 54 medical consultation and disability<sup>1,2</sup>, particularly among adults over 65, where joint, back, 55 and neck pain are common <sup>3,4</sup>. The burden of chronic pain extends beyond physical suffering, 56 as it poses signifanct societal costs through lost productivity and increased healthcare 57 resource utilisation, presenting a major global health challenge<sup>5,6</sup>.

58

59 The International Association for the Study of Pain (IASP) defines pain as an unpleasant 60 sensory and emotional experience. While acute pain serves a protective function by signaling 61 potential or actual tissue damage, chronic pain is defined as pain persisting for more than 62 three months, continuing beyond the normal healing period. Unlike acute pain, which is 63 adaptive, chronic pain is often maladaptive as it no longer serves a protective role. Indeed, 64 chronic pain is increasingly recognised as a distinct condition, with the 2019 ICD-11 65 classification introducing 'chronic primary pain', where pain is the principal problem rather than a result of another disease <sup>7-10</sup>. Chronic pain was traditionally classified as either 66 67 neuropathic pain, which originates from a lesion or disease of the somatosensory nervous 68 system, or nociceptive pain, which results from actual or threatened non-neural tissue 69 damage<sup>8,9</sup>. However, in 2016, a third category—nociplastic pain—was introduced to describe 70 pain arising from altered nociception without clear evidence of tissue or nerve damage. 71 Nociplastic pain, characterised by its widespread and diffuse nature, is particularly 72 debilitating and is best typified by conditions such as fibromyalgia<sup>11</sup>.

73

Despite advances in understanding these pain mechanisms, clinical tools to accurately diagnose and distinguish between them remain lacking. Existing clinical models do not account for the molecular underpinnings that could differentiate nociceptive, neuropathic, and nociplastic pain. Here, proteomics – the large-scale study of proteins – offers a promising avenue. By examining proteins as biomarkers, proteomics offers promising opportunities to improve diagnostic accuracy and support personalised therapeutic strategies for chronic pain.

80

The field of proteomics has significantly advanced our understanding of molecular mechanisms in complex diseases like cardiovascular disease, diabetes, and cancer by integrating genetic, lifestyle, and environmental influences <sup>12</sup>. Given the recognition of pain vulnerability—where genetic and biological factors predispose certain individuals to developing chronic pain<sup>13-15</sup>—proteomic analyses could help identify those at higher risk,

86 facilitating early recognition and intervention. Prior biomarker studies in chronic pain have 87 been limited by small sample sizes and a narrow focus on specific proteins, failing to capture the full complexity of pain mechanisms <sup>16</sup>. By leveraging a comprehensive proteomic dataset 88 89 in a large population-based study, our research addresses this gap and provides an opportunity 90 to identify novel biomarkers associated with pain vulnerability and distinct pain mechanisms 91 <sup>17</sup>. These innovative approaches may offer a deeper understanding of chronic pain 92 mechanisms, opening pathways to improved diagnostic assays and novel therapeutic targets. 93 94 We therefore aimed to: (1) evaluate the proteomic signatures distinguishing acute and chronic

95 pain, identifying unique molecular patterns; (2) assess the diagnostic and prognostic validity 96 of models based on 2,923 unique plasma proteins in predicting widespread chronic pain, 97 comparing their performance to conventional clinical risk models, and to explore the added 98 value of integrating plasma proteins into clinical risk models; and (3) to assess the causal 99 relevance of key identified proteins and their potential as therapeutic targets for the treatment 100 of chronic pain.

### 101 **Results**

# 102 **Baseline Characteristics and Pain Phenotypes**

103 We analysed 29,254 participants with plasma proteomics data (Olink) from the UK Biobank, 104 of whom 44.6% were male, with a median age of 55.8 years (Supplementary Table 2). The 105 comparison of participants with and without proteins is provided in **Supplementary Table 1**. 106 In the present study, 52.3% of participants reported suffering chronic pain at baseline. 107 Regarding pain types, 85.2% reported musculoskeletal pain, 22.5% pain in the head and face, 108 10.7% abdominal pain, and 3.0% experienced widespread pain. Overall, 24.4% of 109 participants reported at least two pain sites affected. A Venn diagram depicting the overlap 110 between different chronic pain types, including widespread chronic pain, is provided in 111 Extended Data Fig. 1. In 2019, data on pain mechanisms were collected from a total of 112 8,225 participants. Among them, 571 reported nociceptive pain, 75 reported neuropathic pain, 113 4,153 experienced nociplastic pain, and 717 had a diagnosis of fibromyalgia 114 (Supplementary Table 2).

115

### 116 **Proteomic Associations with Chronic and Acute Pain**

117 We conducted a proteome-wide association study (PWAS) to evaluate the ability of protein 118 signatures to distinguish chronic pain by comparing protein expression profiles between 119 individuals with chronic pain and pain-free controls. People with chronic pain showed 120 widespread and substantial changes in protein expression compared to pain-free controls. In 121 contrast, those with acute pain showed minimal associations with protein levels (Fig.1A and 122 Extended Data Fig. 2). To assess the difference in protein signatures associated with chronic 123 and acute pain, we analysed the overlap between proteins linked to each condition. Only 27% 124 (234/864) of the proteins associated with chronic pain overlapped with those linked to acute 125 pain, underscoring distinct molecular pathways (Fig.1A and B and Supplementary Table 126 3).

127

In the analysis of widespread chronic pain, the proteins most significantly upregulated compared to controls were CDCP1, IL18R1, GAST, GDF15, LGALS9, GUSB, ASGR1, MRC1, PALM2, and HAVCR2. In contrast, the ten most downregulated proteins were CA14, APOF, PON3, NTRK3, MXRA8, ITGAV, SELENOP, PLTP, EGFR, and ITGA11 (**Fig.1B**). A total of 811 proteins out of 2,923 (27.7%) exhibited significant associations with widespread chronic pain. In the PWAS, 864 out of 2,923 proteins (29.6%) exhibited significant associations with overall chronic pain. Musculoskeletal pain had the highest number of

- 135 significant associations, with 844 proteins (28.9%), followed by abdominal pain with 569
- 136 proteins (19.5%), and head and face pain with 428 proteins (14.6%) (Fig. 1B and
- 137 **Supplementary Table 4**). Several proteins, including APOF, ASGR1, CA14, CA6, MXRA8,
- 138 PLTP, PON3, and RARRES2, were shared across multiple pain types (Fig. 1C).



139

## 140 Figure 1. Proteomic signature of different types of chronic pain and acute pain.

Notes: A, Comparison of proteins significantly associated with both chronic and acute pain. B, Count
of proteins significantly associated with specific types of acute and chronic pain, categorised by panel.
C, Volcano plots show protein associations with different pain types after applying Bonferroni
correction. Proteins with p-values below 0.05/2923 are highlighted in red (positive) and blue

145 (negative), while nonsignificant associations are represented in gray. The top 10 positively and 146 negatively associated proteins with the lowest p-values for each pain type are labelled.

147

## 148 Intricate and sparse proteomic scores (I-ProtS and S-ProtS)

Proteins identified from PWAS for widespread chronic pain and specific chronic pain types were used to derive intricate proteomic scores (I-ProtS) for chronic pain. Additionally, sparse proteomic scores (S-ProtS) were generated using the top 10 proteins associated with widespread chronic pain and specific chronic pain types to evaluate the potential of these sparse plasma protein signatures in distinguishing specific chronic pain types.

154

Higher baseline percentiles of both I-ProtS and S- ProtS correlated with increased prevalence of chronic pain at baseline, both across overall as well as for specific chronic pain types. The associations between I-ProtS and overall chronic pain are illustrated in **Extended Data Fig. 3**, showing a strong correlation coefficient [95% CI]: 0.99 [0.99–1.00]. Across all chronic pain types, S-ProtS showed a distribution similar to I-ProtS and comparable correlations with observed event rates. The association between I-ProtS or S-ProtS and the observed rates of widespread pain differed from that of other specific pain types (**Extended Data Fig. 3**).

162

# 163 **Protein signatures improved classification of widespread chronic pain**

Clinical risk models (CS) incorporating previously<sup>13</sup> identified key risk factors like sleep 164 165 difficulties, neuroticism, powerlessness, mental health issues, life stressors, and obesity 166 achieved a median Area Under the Curve (AUC) of 0.81 (95% CI: 0.76–0.86) for widespread 167 chronic pain. A protein-only model based on S-ProtS showed comparable performance, with 168 an AUC of 0.82 (95% CI: 0.77-0.87). The I-ProtS model achieved numerically higher 169 performance, with an AUC of 0.88 (95% CI: 0.83–0.92). Incorporating I-ProtS into the CS 170 model enhanced discrimination, yielding an AUC of 0.87 (95% CI: 0.83-0.91) for 171 widespread chronic pain. The combined I-ProtS and CS model reached the highest 172 discrimination, with an AUC of 0.92 (95% CI: 0.88-0.94) (Fig. 2A). To assess the 173 interpretability of the classification models, we evaluated their calibration and performed 174 decision curve analyses. For widespread chronic pain, the combined models demonstrated 175 good calibration, as evidenced by a calibration slope of 0.97 (95% CI 0.85–1.10), indicating 176 strong alignment between predicted and observed risks (Extended Data Fig. 4.).

177

178 CS models for chronic pain had AUC ranging from 0.66 to 0.76, with the highest 179 performance observed for abdominal pain (AUC = 0.76, 95% CI: 0.73-0.79). Across the 180 three pain types, the I-ProtS demonstrated comparable performance to the CS model. 181 However, the sparse proteomic score (S-ProtS) model did not achieve superior or comparable 182 performance relative to the CS model for any chronic pain types (Extended Data Fig. 4). 183 Incorporating S-ProtS into the CS model significantly enhanced discrimination for all chronic 184 pain types, with an AUC of 0.69 (95% CI: 0.67–0.70) for Musculoskeletal pain and the best 185 performance for abdominal pain (AUC = 0.81, 95% CI: 0.78-0.83). The addition of I-ProtS 186 to the CS model further improved classification performance beyond that of S-ProtS, with an 187 AUC of 0.91 (95% CI: 0.90-0.92) for head and face pain (Extended Data Fig. 4). The I-188 ProtS-only model showed a net benefit comparable to that of the CS-based models, while the 189 combined models (incorporating I-ProtS or S-ProtS) provided a greater net benefit than 190 models based solely on either CS or I-ProtS alone (Extended Data Fig. 4).





192

### 193 Figure 2. Diagnostic performance of proteomic score, clinical score, and combined

Notes: this figure presents the ROC curves and Area Under the Curve (AUC) for widespread chronic pain. Higher AUC values indicate improved model performance in distinguishing individuals with widespread chronic pain from those without. Abbreviations: CS: clinical risk model; S-ProtS: sparse proteomic score; I-ProtS: intricate proteomic score; CS+S-ProtS: combined model with clinical model and S-ProtS; CS+I-ProtS: combined model with clinical model and I-ProtS.

200

## 201 **Prospective Prediction of Pain Progression and Onset**

202 The stability and individual changes in pain site numbers between baseline and the two

- 203 follow-up visits were shown in Extended Data Fig. 5. We assessed the predictive power of I-
- 204 ProtS and S-ProtS for predicting new widespread pain, pain mechanisms, and pain

progression. Both I-ProtS and S-ProtS demonstrated good predictive discrimination for
fibromyalgia, with AUCs of 0.76 and 0.74, respectively (Fig. 4A). The ProtS showed better
calibration for the nociplastic pain and fibromyalgia (Supplementary Fig.1).

208

Both I-ProtS and S-ProtS for widespread chronic pain were significantly associated with the onset of widespread chronic pain at follow-up visits (**Fig. 4B**). In the pain mechanism classification, I-ProtS and S-ProtS were significantly associated with nociplastic pain and fibromyalgia. However, for nociceptive pain and neuropathic pain, no significant associations were observed for either I-ProtS or S-ProtS (**Fig. 4B**).

214

215 For the onset of specific pain sites, I-ProtS and S-ProtS also showed significant positive 216 associations, although these were weaker for certain pain sites, such as headache, facial pain, 217 and abdominal pain, compared to other chronic pain sites (Fig. 4C and J). Both follow-up 218 visits demonstrated a positive correlation between proteomic scores and pain spread, and a 219 negative correlation with pain recovery. Higher proteomic scores were associated with an 220 increased number of pain sites (multisite chronic pain), while lower scores corresponded with 221 fewer pain sites and greater pain recovery (Fig. 4D, E, K, and L). The proteomic scores, both 222 I-ProtS and S-ProtS, demonstrated a strong association with the number of pain sites at the 223 2019 follow-up (I-ProtS:  $R^2 = 0.692$ , P=0.005; S-ProtS:  $R^2 = 0.693$ , P=0.005) and an even stronger association at the 2022 follow-up (I-ProtS: R<sup>2</sup>=0.849, P<0.001; S-ProtS: R<sup>2</sup>=0.954, 224 225 P<0.001) (Fig. 4C and G).

226

Proteomic scores exhibited a monotonic increase with pain duration, rating of worst pain, pain impact, and pain symptom severity nine years later (**Fig. 4F-I**). The percentage of participants reporting activity limitations due to chronic pain increased across higher proteomic score quantiles (I-ProtS and S-ProtS) (**Fig. 5L**). S-ProtS showed comparable associations with activity limitations related to chronic pain sites, similar to those observed with I-ProtS (**Fig. 4N**).



233

Fig. 4: Prospective associations of pain-specific proteomic scores with mechanism pain

- classification, pain onset, progression, multisite chronic pain, duration, intensity, impact,
- and activity limitations in longitudinal data.

237 Notes: The 2019 follow-up refers to the online follow-up conducted in 2019, and the 2022 238 follow-up refers to the one conducted in 2022. Panel A shows the AUC of I-ProtS and S-239 ProtS for selected pain types. Panel B: Displays the association between the onset of 240 widespread chronic pain, pain mechanism classification, and the proteomic scores (ProtS) in 241 2019. Panels C and J: Show the associations between the onset of chronic pain and the 242 proteomic scores in 2019 and 2022, respectively. "Onset of chronic pain" includes 243 participants who were pain-free at baseline but reported chronic pain at follow-up. Panels D 244 and K: "Pain spreading" refers to participants whose number of pain sites increased, while 245 "pain recovery" refers to those whose pain sites decreased. Panels E and L: Depict the 246 number of pain sites (multisite chronic pain) plotted against quantiles of the Sparse Proteomic 247 Score (S-ProtS) and Intricate Proteomic Score (I-ProtS). Panel F: Shows the proportion of 248 chronic pain duration across quantiles of I-ProtS. Panels J-I: Illustrate the rating of worst pain, 249 impact of pain, and symptom severity, respectively, in relation to quantiles of S-ProtS and I-250 ProtS. Panel M: Illustrates the proportion of activity limitations caused by overall chronic 251 pain among participants with chronic pain. Panel N: Shows activity limitations by specific 252 chronic pain sites. Abbreviations: S-ProtS, Sparse Proteomic Score; I-ProtS, Intricate 253 Proteomic Score.

254

# 255 Contributions of proteins to classification of widespread chronic pain

256 Proteins including CA14, ASAH2, TNFRSF10B, GDF15, SELENOP, CCL20, SCT, IL18R1, 257 VSIG2, LEP, GAST, CELA2A, APOF, IL15, and LGALS3 were identified as key 258 contributors to widespread chronic pain. Among these, CA14 emerged as the most impactful, 259 reflected by its highest SHAP (SHapley Additive exPlanations) value, suggesting a prominent 260 role in pain prediction. ASAH2 and TNFRSF10B followed as major contributors. The SHAP 261 analysis further highlighted the role of LEP, where both high and low levels influenced risk 262 prediction. Elevated LEP values (indicated by yellow) are particularly associated with an 263 increased risk of widespread chronic pain (Fig. 5).

264 SHAP analyses identified several key proteins contributing to the classification of different 265 chronic pain types. LEP consistently emerged as the top predictor, exerting a strong influence 266 on the model. Other proteins, including COL9A1, GAST, SELENOP, and CRTC1, also 267 displayed high SHAP values, underscoring their roles in pain prediction. COL9A1 and GAST 268 demonstrated particularly notable impacts. In specific pain types, proteins such as 269 TNFRSF10B, FETUB, SCT, and ITGAV also contributed significantly to prediction 270 outcomes. GAST and FETUB ranked among the highest contributors in several subsets, 271 while CA14, ASAH2, and PZP emerged as prominent predictors in others (Extended Data 272 Fig. 6). Including participants with cancer did not change the results, as CA14 remained the 273 top-ranking protein (Extended Data Fig. 6).

274





Notes: (A) SHAP plot illustrating the impact of individual proteins on widespread chronic
pain prediction. Brighter colours (yellow) represent higher feature values, while darker
colours (purple) indicate lower feature values, demonstrating how each protein contributes to
the prediction model. (B) Mean SHAP values for the top contributing proteins to widespread
chronic pain. Abbreviations: SHAP, SHapley Additive exPlanations.

282

275

## 283 **Prospective association of Top 15 proteins with pain phenotypes**

We investigated the prospective associations between the levels of the top 15 proteins of the widespread chronic pain, top 15 proteins (CA14, ASAH2, TNFRSF10B, GDF15, SELENOP, CCL20, SCT, IL18R1, VSIG2, LEP, GAST, CELA2A, APOF, IL15, and LGALS3), and mechanism pain classification (nociceptive pain, neuropathic pain, nociplastic pain, and fibromyalgia), the onset, spread, and recovery of chronic pain. Except for CELA2A, the other proteins exhibited significant associations with nociplastic

pain or fibromyalgia. None of the 15 proteins showed significant associations with nociceptive pain or neuropathic pain, indicating that these 14 proteins can effectively distinguish nociplastic pain/fibromyalgia from nociceptive and neuropathic pain up to 9 years in advance (**Fig.6A**). At the 2022 follow-up, the onset and progression of chronic pain showed significant associations with the top 11 proteins, excluding SCT, GAST, CELA2A, and IL15. Among these, CA14, TNFRSF10B, GDF15, VSIG2, and LEP exhibited significant associations with all aspects of chronic pain onset and progression, including pain spreading

and recovery (**Fig. 6A**). The detailed prospective associations between the top 15 proteins and pain mechanism classification (nociceptive pain, neuropathic pain, nociplastic pain, and fibromyalgia), as well as the onset and progression of chronic pain, including non-linear associations, are presented in the **Supplementary Fig.2-16**.

301

# 302 Mendelian Randomisation and Causal Inferences

303 Two-sample Mendelian randomisation (MR) analyses revealed causal effects of genetically 304 predicted levels of 12 proteins (all but ASAH2, IL18R1, and CELA2A) and multisite chronic 305 pain (**Fig. 6B and Supplementary Table 5**). Further colocalisation analyses reinforced the 306 causal relevance of CA14 (H4 = 0.61) with multisite chronic pain (**Fig. 6C and** 307 **Supplementary Table 6**). In the reverse MR, we found no significant association between 308 genetic liability to multisite chronic pain and CA14. However, a significant association was 309 observed with LEP (**Supplementary Table 6**).

The protein-protein interaction (PPI) network revealed that LEP, GDF15, and TNFRSF10B were central nodes, exhibiting multiple connections with other significant proteins such as LGALS3, IL15, and CCL20, suggesting their pivotal roles in chronic pain modulation. In contrast, proteins like CELA2A and APOF were more isolated, indicating potentially peripheral roles in the network (**Extended Data Fig. 7 and Supplementary Table 7**).

315

## 316 **Proteomics-based drug repurposing**

317 Among the top 15 proteins, five (CA14, TNFRSF10B, IL18R1, IL15, and LGALS3) were 318 found in the Open Targets database, highlighting their potential as therapeutic targets 319 (Supplementary Table 8). A total of 11 drugs were identified targeting these proteins, 320 including both small molecules and biologics such as antibodies and proteins, each 321 categorised by drug type and mechanism of action. Notably, CA14 emerged as a key 322 therapeutic target, with sultiame (CHEMBL328660), a carbonic anhydrase inhibitor, as its 323 main associated drug. SULTHIAME, which acts on the plasma membrane (Extended Data 324 Fig. 12), is primarily used for treating obstructive sleep apnea and epilepsy. However, CA14 325 agonists may be a more suitable therapeutic approach, based on the non-linear association of 326 the CA14. Beyond sulthiame, the remaining ten drugs present promising options for treating 327 nociplastic pain





329 Fig 6. Prospective associations, mendelian randomisation results, and drug repurposing

# based on top 15 proteins and their potential causal relationships with chronic pain.

Notes: Panel A: prospective associations between the top 15 proteins and chronic pain. The analysis was adjusted for several confounders, including sleeplessness, frustration, fatigue, mood disturbances, stressful life events, and body mass index (BMI). Prognostic associations for pain onset were estimated among participants who reported no pain at baseline. Panel B: mendelian randomisation and colocalisation results for the top 15 proteins. the colocalisation analysis utilised protein quantitative trait loci (pQTL) data from the UK biobank (UKB) to

identify shared genetic variants between protein levels and pain outcomes. Mendelian
randomisation was conducted to explore potential causal relationships between the top 15
proteins and multisite chronic pain. Panel C: colocalisation analysis for CA14 and multisite
chronic pain. Panel D: identification of potential therapeutic targets based on the top 15
proteins.

342

### 343 Discussion

344 Our analysis revealed marked differences in the protein signatures of chronic versus acute 345 pain. By leveraging these protein changes, we developed pain-specific proteomic scores that 346 not only effectively discriminated individuals with chronic pain from those who were pain-347 free, but also predicted the intensity, phenotype, onset, spread, and recovery of chronic pain, 348 particularly widespread chronic pain, a key feature of nociplastic pain. Notably, a sparse 349 proteomic signature based on the top 10 proteins performed comparably to models based on 350 conventional clinical variables alone. Among the top 15 proteins identified, 12 were 351 significantly linked to these pain mechanisms, with 10 supported by Mendelian 352 randomisation analysis. CA14, identified as the top-ranking protein and supported by both 353 MR and colocalisation analyses, is a known target of sulthiame (CHEMBL328560), 354 suggesting a potential therapeutic target for nociplastic pain conditions such as fibromyalgia.

### 355 Distinct Protein Signatures in Chronic and Acute Pain

356 Chronic pain exhibits more extensive protein changes compared to acute pain. Traditionally, 357 chronic pain is defined primarily by its duration and lacks specific biomarkers to guide 358 clinical management. Our study addresses his challenge by identifying distinct proteomic 359 signatures that differentiate between chronic and acute pain, suggesting that proteomic 360 information could predict those who will transition from acute to acute pain. Previous 361 research has highlighted the utility of proteomics in understanding pain sensitivity, especially in experimental models<sup>18</sup>. Notably, several proteins identified in our study provide novel 362 363 insights into the biological pathways involved in pain mechanisms, in particular highlighting 364 the involvement of metabolic and immune pathways in chronic pain development and 365 persistence. For instance, leptin (LEP), known for its role in energy regulation, was strongly 366 associated with chronic pain, indicating the potential involvement of metabolic dysregulation. 367 Additionally, proteins such as ASGR1 and RARRES2, involved in immune responses, 368 highlight the role of inflammation in chronic pain mechanisms. Inflammatory biomarkers 369 may aid in predicting high-risk groups for developing nociplastic pain and guide the 370 development of tailored treatments.

371

The distinct molecular profiles observed across specific pain types, such as head and face pain, abdominal pain, and musculoskeletal pain, further emphasise the heterogeneity of chronic pain. However, the identification of shared proteins across multiple pain types such as APOF and ASGR1— suggests that there may be common underlying biological

18

376 mechanisms driving pain across body regions. This finding could pave the way for the

development of universal biomarkers that apply across multiple pain syndromes.

378

## 379 Classification Accuracy of Proteomic Profiling

380 We demonstrate that proteomic profiling can perform as well as conventional clinical risk 381 scores in predicting chronic pain and its progression. Moreover, combining proteomic scores 382 with clinical variables further enhances predictive performance, suggesting that an integrated 383 approach may be beneficial. This study is the first to comprehensively demonstrate the 384 predictive power of plasma proteins across a broad spectrum of chronic pain types. We 385 achieved this by directly comparing proteomic data with clinical variables and evaluating the 386 added predictive value that proteomics offers beyond traditional clinical predictors. The 387 proteomic score alone exhibited high predictive accuracy for chronic pain and its various 388 subtypes. This predictive performance was further enhanced when proteomic data were 389 combined with clinical variables. Our findings underscore the substantial potential of 390 proteomic profiling as a promising technique to complement clinical evaluation, aiding in 391 both the risk assessment for transition to chronic pain and the prognostication of chronic pain 392 outcomes.

393

394 The proteomic score demonstrated a strong association with the onset, spread, and recovery 395 of chronic pain. This profile effectively identifies individuals at higher risk for developing 396 chronic pain, experiencing its spread to new sites, and their likelihood of recovery. Pain is influenced by a complex interplay of biological, psychological, and social factors <sup>13</sup>. Proteins 397 398 integrate genetic, environmental, age-related, behavioural, and medication influences, 399 offering comprehensive insights into pain mechanisms. Previous research has suggested that 400 pain spread is not random but shows strong dependencies between adjacent pain sites <sup>13</sup>. Our 401 study supports this by revealing significant associations between pain-specific proteomic 402 scores and pain at various sites. Additionally, we observed robust correlations between 403 proteomic scores and pain recovery, indicating shared biological foundations for both the 404 spread and recovery of pain.

405

The proteomic score demonstrated a significant and specific association with nociplastic pain and fibromyalgia, distinguishing them from nociceptive and neuropathic pain. Nociplastic pain is characterised by abnormal sensory processing without clear peripheral damage. The association between proteomic score and nociplastic pain suggests that proteomic signatures

410 capture the complex biological underpinnings of this condition, including abnormalities in

411 sensory perception, a hallmark feature<sup>11</sup>.

412

# 413 Causal Relevance and Therapeutic Potential of Key Proteins

414 Carbonic anhydrase 14 and leptin were identified as the primary proteins consistently 415 associated with chronic pain, particularly nociplastic pain and fibromyalgia, and progression 416 of chronic pain (onset, spreading, and recovery of chronic pain) in both longitudinal analyses. 417 carbonic anhydrase 14, identified here for the first time as associated with chronic pain, 418 plays an important role in neuronal signal transmission via zinc ion binding and carbonate 419 dehydratase activity. It is primarily enriched in the spinal cord and has crucial for neuronal 420 function. Leptin is involved in immune regulation and inflammation, contributing to pain 421 modulation, especially in nociplastic pain. Fibromyalgia affects 10-48% of patients with 422 rheumatic diseases, compared to ~2-6% in the general population, likely due to shared mechanisms of immune dysregulation and inflammation<sup>19-21</sup>. Both leptin and gastrin showed 423 424 positive correlations with new-onset pain and pain spread, suggesting their role in the 425 development and propagation of chronic pain. This relationship is further supported by their 426 impact on pain recovery outcomes. Animal studies have demonstrated that leptin can 427 influence pain thresholds <sup>22,23</sup>. Together, these proteins suggest potential complementary roles 428 in pain, with leptin influencing inflammation and carbonic anhydrase 14 affecting neuronal 429 signalling.

430

431 The role of carbonic anhydrase 14 and leptin were both supported by mendelian 432 randomisation, with carbonic anhydrase 14 further validated through colocalisation analysis. 433 Our search on the Open Targets platform revealed that carbonic anhydrase 14 is the target of 434 an approved small molecule drug, sulthiame, which is currently used to treat epilepsy and 435 obstructive sleep apnoea. However, there are currently no well-documented drugs that 436 activate CA14. Most research on carbonic anhydrase modulation has centered on inhibitors 437 rather than activators, as seen with sulthiame in epilepsy treatment. If enhancing CA14 438 activity proves to be therapeutically relevant for pain management, future research will need 439 to focus on developing specific agonist or allosteric modulators. In addition to carbonic 440 anhydrase 14, drugs for four other proteins were identified, primarily used for cancer and 441 autoimmune diseases. While these therapies carry potential risks related to immune 442 modulation, they remain possibilities for treatment options. Carbonic anhydrase 14, the top-

443 ranked protein with a strong causal association, suggests that targeting this protein could offer

444 a promising therapeutic avenue for nociplastic pain.

## 445 Limitations and strengths

446 While our study provides strong evidence for the role of proteomic profiling in 447 characterisitng chronic pain, there are limitations which warrant discussion. First, while 448 proteomic profiling demonstrated predictive value, the Olink panels used may have excluded 449 key proteins relevant to chronic pain, potentially limiting the comprehensiveness of our 450 analysis. Future studies should incorporate a wider array of proteomic markers to capture a 451 more complete picture of the biological pathways involved in chronic pain. Second, the focus 452 was primarily on a specific subset of pain types. Other pain characteristics not included may 453 have different proteomic profiles and predictors. Furthermore, some participants in the 454 control group, despite being classified as pain-free, may have had a history of chronic pain. 455 Third, the study population was predominantly white British, which may limit the 456 generalizability of the findings to other ethnic groups. Proteomic profiles and pain 457 associations could vary across different genetic backgrounds. Fourth, while leptin and 458 carbonic anhydrase 14 showed a causal relationship with pain, potential protein-protein 459 interactions were not considered. The underlying biological pathways also remain unclear, 460 warranting further research. Fifth, the findings have not been validated in independent 461 cohorts. External validation in other large and diverse populations is necessary to confirm the 462 robustness and applicability of the results. Finally, we acknowledge that the MR findings 463 would be more robust if there were evidence indicating that the pQTLs and genetic variations 464 associated with the outcome are shared. However, we also recognise that the lack of 465 colocalisation evidence does not undermine the validity of the results, as colocalisation 466 methods are known to have a high false-negative rate, typically around  $60\%^{24}$ .

467

### 468 Conclusion

469 In conclusion, this study underscores the significant potential of proteomic profiling to 470 advance our understanding and management of chronic pain, particularly nociplastic pain and 471 fibromyalgia. By identifying key proteins such as **carbonic anhydrase 14** and **leptin**, we 472 offer new insights into biological mechanisms underlying pain. Therapies targeting 473 TNFRSF10B, like tigatuzumab, represent promising candidates for drug repurposing in 474 chronic pain treatment trials. Although no CA14 agonists are currently available, CA14 475 remains a highly promising target, encouraging future efforts to develop novel therapies that 476 leverage its potential in pain modulation.

477

#### 478 Methods

### 479 Study population

480 The UK Biobank is a prospective, population-based cohort comprising over 500,000 481 individuals aged 40-69, recruited from 22 assessment centers across the UK between 2006 482 and 2010. In 2019, additional online surveys were conducted to track specific pain-related 483 outcomes over time. A random sample of participants (n=53,029) were selected for the 484 measurement of proteomics data and thus included for the subsequent analyses. More details 485 of study design, cohort construction, and study window is provided in Extended Data Fig. 8 486 and Extended Data Fig. 9. Ethical approval was obtained from the North West Multi-centre 487 Research Ethics Committee (MREC, https://www.ukbiobank.ac.uk/learn-more-about-uk-488 biobank/about-us/ethics), with all participants providing written informed consent. This 489 research was approved under application number 98,358. 490

- To reduce confounding effects from cancer diagnosis or treatment, participants with cancer-
- 491 related pain were excluded, allowing the focus to remain on chronic non-cancer pain.
- 492 Additionally, participants selected by the UK Biobank Pharma Proteomics Project (UKB-PPP)
- 493 Consortium were excluded from the analyses.

### **Clinical variables** 494

495 Six variables capturing biological, psychological, and social factors were included as 496 predictors for the construction of a clinical model. They were specified in prior with literature evidence suggesting their predictive value for chronic pain <sup>13</sup>. The factors were collected by 497 498 an standardised touchscreen questionnaire in UK Biobank and include sleep difficulties 499 (difficulty falling asleep, rated as quite a lot or very much), neuroticism (perceived life effort 500 as constant, rated as quite a lot or very much), powerlessness (feelings of lack of energy or 501 powerlessness, rated as quite a lot or very much), mental health issues (history of diagnosis or 502 treatment by a doctor), life stressors (events such as divorce, death of a partner, or significant unemployment history), and a BMI over 30kg/m<sup>2</sup>. All the variables listed above were 503 504 transformed into binary variables.

### 505 **Proteomic profiling**

506 The UK Biobank Pharma Proteomics Project consortium has generated extensive blood-507 based proteomic data. Proteomic profiling was conducted on EDTA-plasma samples from a 508 cohort of 54,893 UKB participants at baseline recruitment, derived from a randomised subset 509 representative of the broader UKB population. Utilising the Olink Explore 1536 and 510 Expansion platforms, the profiling encompassed 2,923 unique proteins, assessed through 511 2,941 assays. The protein targeting assays are organised into four 384-plex panels:

512 Inflammation, Oncology, Cardiometabolic, and Neurology. Detailed methodologies 513 concerning assay execution, sample selection, and handling are available in the online 514 document (https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=1839). No notable impacts 515 from batch and plate variations, nor anomalies in protein coefficients of variation (CVs), were 516 detected. The inter- and intraplate CVs for all OLINK panels remained below 20% and 10%, 517 respectively, with a median protein CV of 6.7%. There were strong correlations observed for 518 identical proteins across different panels and between the OLINK assay and independent 519 assays within the UK Biobank. The proteomics data were provided as Normalised Protein 520 eXpression (NPX) values on a log<sub>2</sub> transformation.

This analysis focuses on participants with less than 50% missing proteomic data. Additionally, three proteins missing in over 50% of participants were excluded. Post-quality control, missing NPX values were imputed using chained random forests, incorporating age and sex as predictors in the imputation process. The NPX data of proteins were standardised to have a mean of 0 and a variance of 1, following a standard normal distribution.

## 526 Baseline pain phenotype

527 At the baseline recruitment between 2006 and 2010, 501,243 participants were asked about 528 pain experiences that interfered with their usual activities in eight major body regions in the 529 past one month.

530 Participants who reported pain at a specific site in the past month were subsequently asked 531 whether the pain had persisted for more than three months. This follow-up question was used 532 to define chronic pain (pain persisting for more than three months) and acute pain (having 533 pain in last one month but persisting for three months or less). Among the eight painful 534 locations specifically asked in the questionnaire, we grouped them into four categories based 535 on the similarity of underlying aetiologies and conditions: (1) headache and facial pain, 536 which may reflect conditions like migraines or tension headaches; (2) abdominal pain, 537 potentially linked to visceral causes such as irritable bowel syndrome (IBS) or endometriosis; 538 (3) musculoskeletal pain (neck or shoulder pain, hip pain, and knee pain), which may indicate 539 localized mechanical or inflammatory issues; and (4) widespread pain ("pain all over the 540 body"), often associated with conditions like fibromyalgia. For widespread pain, participants 541 who reported experiencing it were not given the option to select other specific body regions.

## 542 Longitudinal Pain Phenotypes

## 543 **Online UK Biobank in 2019 - Pain mechanism classification:**

544 Pain outcomes were classified based on participants' chronic pain status and diagnostic 545 criteria derived from validated scales. In 2019, participants were invited to complete an

online pain questionnaire that incorporated the 2016 revised Fibromyalgia Survey Criteria

547 (FSC)  $^{25}$  and the Douleur Neuropathique 4 (DN4) $^{26}$ .

548 **Douleur Neuropathique 4 (DN4)**: The DN4 is a seven-item questionnaire designed to assess 549 neuropathic pain. In the UK Biobank study, an abbreviated version was used, omitting the 550 clinical examination assessment. Scores range from 0 to 7, with a score of  $\geq$ 3 indicating the 551 presence of neuropathic pain. Although primarily used to diagnose neuropathic pain, the DN4 552 may also reflect central sensitisation, a key feature of nociplastic pain<sup>27</sup>.

553 **Fibromyalgia Survey Criteria (FSC)**: The FSC is based on the 2016 ACR Fibromyalgia 554 Survey Criteria<sup>25</sup> and consists of two components: the **Widespread Pain Index (WPI)**, 555 which measures pain across 19 body areas (score 0-19), and the **Symptom Severity Scale** 556 (**SSS**), which assesses somatic symptoms including fatigue, sleep disturbances, and cognitive 557 difficulties (score 0-12). The total score (range 0-31) is calculated by combining the WPI and

558 SSS scores.

559 The WPI was used to assess the severity of nociplastic pain, while the DN4 helped to identify 560 both neuropathic pain and potential central sensitisation, providing a comprehensive 561 evaluation of different pain types.

562

563 Based on these criteria, participants were classified into four distinct pain categories:

Nociceptive pain was defined for participants with chronic pain but no neuropathic characteristics (DN4 score = 0) and an FSC score <3, indicating a low likelihood of nociplastic pain. Participants without chronic pain were classified as having no nociceptive pain.

568 Neuropathic pain was defined for participants with chronic pain and a DN4 score  $\geq 3$ 569 suggesting the presence of neuropathic pain. Participants with an FSC score  $\geq 3$  were 570 excluded to reduce the likelihood of including those with possible nociplastic or 571 fibromyalgia-related pain.

572 **Nociplastic pain** was defined for participants exhibiting DN4 ≥3 or a total WPI and SSS 573 score >12. Notably, universally accepted diagnostic criteria for nociplastic pain remain absent. 574 Fibromyalgia, widely recognized as the prototypical manifestation of nociplastic pain, 575 highlights the utility of the FSC score as an effective marker of symptom severity. In addition, 576 the FSC score may reliably reflect the burden of nociplastic pain<sup>28</sup>. Accordingly, an FSC 577 score ≥12 serves as a practical threshold for identifying individuals likely to experience 578 nociplastic pain as the predominant driver of their chronic pain.

579 **Fibromyalgia** was identified either through self-reported diagnoses from baseline or the 580 2019 questionnaires or via general practitioner records. Additionally, participants with a WPI

- and SSS combined score >12 were classified as having fibromyalgia<sup>28</sup>.
- 582

583 **Online UK Biobank in 2019 - Pain sites:** Participants were inquired about experiencing 584 pain or discomfort, either constantly or intermittently, for a duration exceeding three months. 585 They were then requested to specify the affected sites, which included the head, face, neck, 586 shoulders, chest, stomach, abdomen, back, hip, legs, knees, feet, arms, hands, and widespread 587 body pain.

588 **New onset pain:** Participants who did not report any chronic pain at baseline but reported 589 chronic pain at the follow-up visit were defined as having onset of pain.

590 Spreading chronic pain: The spreading of chronic pain was assessed by monitoring changes 591 in the number of chronic pain sites. An increase in the number of pain sites at the follow-up

- 592 visit compared to the baseline visit was defined as pain spread.
- 593 Recovery of Chronic Pain: Recovery of chronic pain was defined as a decrease in the 594 number of pain sites at the follow-up visit compared to the baseline visit.
- 595 **Duration of Pain**: Participants reporting chronic pain were asked to specify the duration of
- 596 their discomfort through the online questionnaire, selecting from the following categories: 3–
- 597 12 months, 1–5 years, or more than 5 years.

598 Pain Rating in the Last 24 Hours: Participants were also asked to rate their pain intensity at

599 each reported chronic pain site over the preceding 24 hours using a numeric rating scale of 0

to 10, where 0 represented no pain and 10 indicated the worst possible pain.

Worst Pain Rating: Participants were prompted to rate the most severe pain they had experienced in the last 24 hours at the chronic pain site that bothered them the most, again on a numeric rating scale from 0 (no pain) to 10 (the worst imaginable pain). or widespread pain, a separate questionnaire ("All-over body pain in the last three months and rating of pain") was used. The ratings from specific body sites and the overall widespread pain were combined for analysis.

607 Pain Interference: The impact of pain on daily functioning was evaluated across seven 608 domains: general activity, mood, walking ability, normal work, relationships with others, 609 sleep, and enjoyment of life. Each domain was rated on a scale of 0 to 10, where 0 indicated 610 no interference and 10 signified complete interference. A total pain interference score was 611 derived by summing the individual scores for these seven items.

612 **Symptom Severity**: Participants were asked to report the severity of three symptoms— 613 fatigue, sleep quality, and cognitive symptoms—over the past week, as measured by the 614 fibromyalgia symptom severity scale. Each symptom was rated on a scale from 0 (no 615 problem) to 3 (severe, pervasive, continuous, and life-disrupting issues). The total symptom 616 severity score was calculated by summing the scores for fatigue, sleep quality, and cognitive 617 symptoms.

618 **Online UK Biobank in 2022- Pain sites:** In 2022, the UK Biobank conducted an online 619 survey to assess pain at various anatomical sites among participants. Respondents were asked 620 to identify current pain in specific areas, including the neck, back, chest, abdomen, legs, 621 muscles, and joints. Additionally, participants provided information on the duration of the 622 pain and the degree to which each site of pain impacted their daily lives. Pain persisting for 623 more than twelve weeks was classified as chronic pain.

The onset of chronic pain, spreading chronic pain, recovery of chronic pain in the follow-up

questionnaire 2022 was also defined followed the phenotype at follow-up questionnaire 2019.

626

## 627 Statistical analyses

# 628 Proteomic score

629 We employed a rigorous four-step machine learning framework (Extended Data Fig.10), 630 which included: (1) feature selection through protein-wide association studies (PWAS), (2) 631 development of a XGBOOST (Extreme Gradient Boosting) model for intricate proteomic 632 scores (I-ProtS) based on all proteins with significant associations after Bonferroni correction, 633 (3) development of a XGBOOST for sparse proteomic scores (S-ProtS) based on the top 10 634 proteins ranked by SHAP value, and (4) model validation. XGBoost is a high-performance 635 machine learning algorithm designed for efficiency, flexibility, and portability, utilizing parallel tree boosting to develop the protein-profiling model<sup>29</sup>. 636

637

## 638 Feature Selection

All participants were included in the feature selection phase. A protein-wide association study was conducted on 2,923 proteins using a binomial regression model with Bonferroni correction. Proteins with p-values less than Bonferroni-corrected p-value (0.05/2923), were selected for the development of the GBM (gradient boosting machines) to generate the painspecific proteomics scores.

644 The proteins identified by the protein-wide association study, associated with specific chronic 645 pain, represent the protein signature. To explore these protein signatures in distinguishing

646 chronic from acute pain, acute pain — typically transient and driven by environmental factors
647 — was used as a negative control to confirm the specificity of the protein signatures
648 associated with chronic pain.

649

## 650 **Proteomic score development**

651 We developed a series of XGBOOST models to assess the potential of plasma proteomics as 652 a single-domain assay for predicting widespread chronic pain. For each pain type, a separate 653 XGBOOST model was constructed using 10-fold cross-validation, a technique employed to 654 minimise the risk of random error caused by data splitting. The predicted risk values from 655 these models were designated as proteomic scores (intricate proteomic scores, I-ProtS). To 656 identify the most important proteins contributing to the prediction of each pain type, we used 657 SHAP (Shapley Additive exPlanations) values. SHAP values are derived from cooperative 658 game theory and provide a unified measure to explain the contribution of each feature—in 659 this case, each protein—to the model's prediction. A positive SHAP value indicates that the 660 protein increases the predicted risk for widespread chronic pain, while a negative SHAP 661 value suggests the protein decreases the predicted risk. For each pain type, the top 15 proteins 662 were ranked based on their SHAP values, indicating their relative importance in the model. 663 SHAP plots were also generated to visually interpret the impact of each protein on the 664 model's predictions, allowing for a clear understanding of how specific proteins influence the 665 risk predictions for widespread chronic pain.

666 Based on the top 10 proteins, we developed an additional XGBOOST model to generate a 667 spare-proteomic-score (S-ProtS), focusing on a more compact set of features. This model 668 aims to reduce complexity while maintaining predictive power, leveraging only the most 669 important proteins identified from the previous analysis.

### 670 Model for pain prediction

671 We fitted GBM models incorporating different sets of clinical predictors (Extended Data 672 **Fig.11**). Specifically, 80% of participants were designated for training, while 20% were used 673 for validation. We developed models based on six predictors identified from a previous study, 674 utilizing 10-fold cross-validation. Additionally, we created models combining these six 675 clinical predictors with proteomic score to evaluate their additive predictive value. Model 676 performance was assessed using AUC, ranging from 0.5 (non-informative) to 1 (perfect 677 discrimination). Calibration plots were employed to visualise the agreement between 678 predicted risks and observed pain rates, while net benefit curves illustrated the additive 679 predictive value of ProRS alongside different clinical predictor sets.

680 We reported key predictive metrics, including the area under the Receiver Operating 681 Characteristic (ROC) curve (AUC). Calibration was evaluated using calibration plots and 682 quantified through the calibration slope statistic, with a slope of 1 indicating optimal overall 683 calibration. All models underwent development and evaluation through 10-fold cross-684 validation, with continuous variables standardised and categorical variables one-hot encoded. 685 The results for all participants, including those with cancer, are provided as a sensitivity 686 analysis in the supplementary materials to assess whether the presence of cancer affects the 687 contribution of proteins.

## 688 **Prospective association of the proteomic score**

To evaluate the prognostic association of the widespread chronic pain-specific proteomic score, Poisson regression was employed to estimate the relationship between the proteomic score (quantile 5 vs quantile 1) and nociceptive pain, neuropathic pain, nociplastic pain, fibromyalgia, onset chronic pain, pain spread, and pain recovery. For onset pain, the analysis focused on participants without any chronic pain at baseline who developed onset pain by the follow-up visit.

## 695 **Prospective association of the top proteins**

The top 15 proteins were identified as those with significant contributions to widespread chronic pain. Poisson regression was employed to estimate the prognostic association between these top proteins and pain mechanism classification (nociceptive pain, neuropathic pain, nociplastic pain, and fibromyalgia), new onset chronic pain, pain spread, and pain recovery (quantile 5 vs quantile 1). The analysis was adjusted for variables including sleeplessness, feeling fed-up, tiredness, mood, stressful life events, and BMI.

To explore dose-response relationships between the top proteins and pain outcomes, restricted cubic spline (RCS) regression was used, with the same multivariable adjustments. Nonlinearity was tested using the likelihood ratio test, and the number of nodes was selected based on the lowest Akaike Information Criterion (AIC) value. The same analytical approach was applied to the other top 15 proteins.

707

## 708 Causal relevance of the top proteins (Mendelian Randomisation Analysis)

709 To explore the causal relationship between specific proteins and pain, we conducted a two-

sample Mendelian randomisation (MR) analysis. This study targeted the top 2 shared proteins

- frequently appearing among the top ten across pain types: leptin (LEP) and gastrin (GAST).
- 712 Selection of genetic instruments: Instrumental variables were derived from two large-scale
- 713 genome-wide association studies (GWAS): the UK Biobank Pharma Proteomics Project

714 (UKB-PPP). 1. All SNPs MR Analysis: Single nucleotide polymorphisms (SNPs) 715 significantly associated with the expression of specific proteins in blood were selected as instrumental variables (p < 5  $\times$  10<sup>15</sup>). To minimise the influence of strong linkage 716 717 disequilibrium (LD) on the outcomes, SNPs with low weak LD ( $R^2 < 0.1$ ) within a 10000 kb 718 window, as estimated using the 1000 Genomes European panel, were included. Additionally, 719 F-statistics > 10 were applied to ensure sufficient instrumental strength related to exposure 720 traits. 2. Cis-SNPs MR Analysis: Cis-SNPs associated with the top shared plasma proteins at 721 genome-wide significance ( $p < 5 \times 10^{-5}$ ) and LD ( $\mathbb{R}^2 < 0.1$ ) were utilised as instrumental 722 variables. Cis-SNPs were defined as those located within 5 Mb of the gene encoding the 723 protein, with LD estimated based on the 1000 Genomes European panel. Furthermore, F-724 statistics > 10 were applied to ensure adequate instrumental strength associated with exposure 725 traits. This analysis was considered the primary MR result due to its proximal relevance to 726 the gene encoding the protein.

Reverse MR analysis: The reverse MR used SNPs associated with multisite chronic pain at p  $< 5 \times 10^{18}$ . Only SNPs with R<sup>2</sup> < 0.001 within a 10,000 kb window were included, and all instruments had an F-statistic > 10.

730 Protein source: UKB-PPP.

Pain sources: To avoid potential bias arising from population diversity, we restricted the genetic background in our drug target MR analysis to participants of European descent. We extracted multisite chronic pain data from a large cohort of GWAS<sup>30</sup>, which included 73,082 cases and 105,474 controls from the latest UK Biobank datasets.

735 Sensitivity analysis

736 The Steiger test was employed to assess potential reverse causality in the MR analysis. 737 Additionally, the bidirectional Mendelian randomisation approach was used to explore the 738 reverse causal relationship between multisite chronic pain and specific proteins. Associations 739 between cis-pQTLs and outcomes were calculated as beta with corresponding confidence 740 intervals (CIs) using the random-effects inverse-variance weighted (IVW) method. 741 Furthermore, MR-PRESSO was utilised to detect outlier genetic variants. The MR-Egger 742 intercept test was conducted to evaluate horizontal pleiotropy, and Cochrane's Q value was 743 calculated to assess heterogeneity in IVW estimators, with P < 0.05 indicating evidence of 744 heterogeneity.

## 745 Colocalisation analysis

746 We performed colocalisation analysis to determine whether the observed associations 747 between the top shared proteins and multisite chronic pain were driven by linkage

748 disequilibrium. For each locus, a Bayesian framework was applied to evaluate support for 749 five mutually exclusive hypotheses: (1) no association with either trait; (2) association with 750 trait 1 only; (3) association with trait 2 only; (4) both traits are associated but have distinct 751 causal variants; and (5) both traits are associated and share the same causal variant. The 752 analysis yielded posterior probabilities for each hypothesis (H0, H1, H2, H3, and H4). We 753 assigned prior probabilities as follows: the SNP being associated with trait 1 only (p1) was set 754 at  $1 \times 10$   $\square$ ; the SNP being associated with trait 2 only (p2) at  $1 \times 10$   $\square$ ; and the SNP being 755 associated with both traits (p12) at  $1 \times 10^{\Box}$ . Strong evidence of colocalisation was defined 756 as a posterior probability for shared causal variants (PH4)  $\ge 0.8$ , while medium evidence was 757 indicated by 0.5 < PH4 < 0.8.

## 758 **Protein-protein interaction (PPI)**

We performed protein-protein interaction (PPI) analysis for the top 15 proteins identified in our models using the **STRING database** (<u>https://string-db.org/</u>)<sup>31</sup>. STRING offers comprehensive interaction networks derived from experimental data, computational predictions, and known biological pathways. This analysis enabled us to examine potential interactions between the top proteins and to identify biologically relevant networks that may be involved in the pathogenesis of widespread chronic pain.

## 765 Drug Repurposing

766 To explore the potential for drug repurposing, we searched the Open Targets platform <sup>32</sup> for 767 the top 15 proteins identified in our analysis. Open Targets integrates data from multiple 768 sources, including genetic associations, known drug interactions, and disease pathways, to 769 evaluate the therapeutic potential of various proteins. This search enabled us to determine 770 whether any of the top proteins were associated with existing drugs that could be repurposed 771 for chronic pain treatment. By identifying proteins already targeted by approved or 772 investigational drugs, we aimed to uncover opportunities for repurposing these drugs to 773 address widespread chronic pain. This approach may offer faster and more cost-effective 774 therapeutic options by leveraging drugs that have already undergone substantial testing for 775 safety and efficacy in other conditions.

776

All modeling and statistical analyses were performed using R software (V4.3.0). Missing
value imputation was conducted using the missRanger package. The XGBOOST and gradient
boosting model (GBM) was implemented with the caret package, with calibration curves
generated by the CalibrationCurve package and net benefit curves by the rmda package. The

- 781 two-sample Mendelian randomisation analysis was conducted using the TwosampleMR
- 782 package. Colocalisation analysis was carried out with the *coloc* package.

783	
784	Reference

- Zimmer, Z., Fraser, K., Grol-Prokopczyk, H. & Zajacova, A. A global study of pain prevalence across 52 countries: examining the role of country-level contextual factors. *Pain* 163, 1740-1750 (2022).
- 788 2. Tompkins, D.A., Hobelmann, J.G. & Compton, P. Providing chronic pain management in the "Fifth Vital Sign" Era: Historical and treatment perspectives on a modern-day medical dilemma. *Drug Alcohol Depend* **173 Suppl 1**, S11-S21 (2017).
- 791 3. Pleis, J.R., Ward, B.W. & Lucas, J.W. Summary health statistics for U.S. adults:
  792 National Health Interview Survey, 2009. *Vital Health Stat 10*, 1-207 (2010).
- Husky, M.M., Ferdous Farin, F., Compagnone, P., Fermanian, C. & Kovess-Masfety,
  V. Chronic back pain and its association with quality of life in a large French
  population survey. *Health Qual Life Outcomes* 16, 195 (2018).
- 5. Soni, A., *et al.* Hospitalization in fibromyalgia: a cohort-level observational study of
  in-patient procedures, costs and geographical variation in England. *Rheumatology*(*Oxford*) 59, 2074-2084 (2020).
- 799 6. Phillips, C.J. The Cost and Burden of Chronic Pain. *Rev Pain* **3**, 2-5 (2009).
- Raja, S.N., *et al.* The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain* 161, 1976-1982 (2020).
- 802
   8.
   Treede, R.D., *et al.* A classification of chronic pain for ICD-11. *Pain* **156**, 1003-1007

   803
   (2015).
- 804 9. Treede, R.D., *et al.* Chronic pain as a symptom or a disease: the IASP Classification
  805 of Chronic Pain for the International Classification of Diseases (ICD-11). *Pain* 160,
  806 19-27 (2019).
- 807 10. Gatchel, R.J., Peng, Y.B., Peters, M.L., Fuchs, P.N. & Turk, D.C. The biopsychosocial approach to chronic pain: scientific advances and future directions. *Psychol Bull* 133, 581-624 (2007).
- 810 11. Kaplan, C.M., *et al.* Deciphering nociplastic pain: clinical features, risk factors and
  811 potential mechanisms. *Nat Rev Neurol* 20, 347-363 (2024).
- 812 12. Carrasco-Zanini, J., *et al.* Proteomic signatures improve risk prediction for common
  813 and rare diseases. *Nat Med* 30, 2489-2498 (2024).
- 814 13. Tanguay-Sabourin, C., *et al.* A prognostic risk score for development and spread of
  815 chronic pain. *Nat Med* 29, 1821-1831 (2023).
- 816 14. Nielsen, C.S., Knudsen, G.P. & Steingrimsdottir, O.A. Twin studies of pain. *Clin*817 *Genet* 82, 331-340 (2012).
- 818 15. Abboud, C., *et al.* Animal models of pain: Diversity and benefits. *J Neurosci Methods*819 348, 108997 (2021).
- B20 16. Gottesman-Katz, L., Latorre, R., Vanner, S., Schmidt, B.L. & Bunnett, N.W. Targeting
  G protein-coupled receptors for the treatment of chronic pain in the digestive system. *Gut* 70, 970-981 (2021).
- Benk, F., McMahon, S.B. & Tracey, I. Pain vulnerability: a neurobiological perspective. *Nat Neurosci* 17, 192-200 (2014).
- 825 18. Segelcke, D., et al. BLOOD PROTEOMICS AND PAIN A TRANSLATIONAL
  826 STUDY TO PROGNOSTICATE PAIN PHENOTYPES AND ASSESS NEW
  827 BIOMARKERS FOR PREVENTING PAIN IN HUMANS.
  828 2024.2007.2004.24309933 (2024).
- Wolfe, F., Ross, K., Anderson, J., Russell, I.J. & Hebert, L. The prevalence and characteristics of fibromyalgia in the general population. *Arthritis Rheum* 38, 19-28 (1995).

- Walitt, B., Nahin, R.L., Katz, R.S., Bergman, M.J. & Wolfe, F. The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. *PLoS One* 10, e0138024 (2015).
- 835 21. Murphy, A.E., Minhas, D., Clauw, D.J. & Lee, Y.C. Identifying and Managing
  836 Nociplastic Pain in Individuals With Rheumatic Diseases: A Narrative Review.
  837 Arthritis Care Res (Hoboken) 75, 2215-2222 (2023).
- Tian, Y., *et al.* Leptin enhances NMDA-induced spinal excitation in rats: A functional link between adipocytokine and neuropathic pain. *Pain* 152, 1263-1271 (2011).
- Rodgers, H.M., Liban, S. & Wilson, L.M. Attenuated pain response of obese mice
  (B6.Cg-lep(ob)) is affected by aging and leptin but not sex. *Physiol Behav* 123, 80-85
  (2014).
- 843 24. Hukku, A., *et al.* Probabilistic colocalization of genetic variants from complex and
  844 molecular traits: promise and limitations. *Am J Hum Genet* 108, 25-35 (2021).
- 845 25. Wolfe, F., Egloff, N. & Hauser, W. Widespread Pain and Low Widespread Pain Index
  846 Scores among Fibromyalgia-positive Cases Assessed with the 2010/2011
  847 Fibromyalgia Criteria. *J Rheumatol* 43, 1743-1748 (2016).
- 848 26. Bouhassira, D., *et al.* Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire
  850 (DN4). *Pain* **114**, 29-36 (2005).
- Rutter-Locher, Z., *et al.* A systematic review and meta-analysis of questionnaires to
  screen for pain sensitisation and neuropathic like pain in inflammatory arthritis. *Semin Arthritis Rheum* 61, 152207 (2023).
- 854 28. Wolfe, F., Walitt, B.T., Rasker, J.J., Katz, R.S. & Hauser, W. The Use of
  855 Polysymptomatic Distress Categories in the Evaluation of Fibromyalgia (FM) and FM
  856 Severity. *J Rheumatol* 42, 1494-1501 (2015).
- 857 29. Xue, T., *et al.* Extracellular vesicle biomarkers for complement dysfunction in schizophrenia. *Brain* 147, 1075-1086 (2024).
- 30. Johnston, K.J.A., *et al.* Genome-wide association study of multisite chronic pain in UK Biobank. *PLoS Genet* 15, e1008164 (2019).
- Szklarczyk, D., *et al.* The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res* 51, D638-D646 (2023).
- 32. Ochoa, D., *et al.* Open Targets Platform: supporting systematic drug-target identification and prioritisation. *Nucleic Acids Res* 49, D1302-D1310 (2021).
- 866

867